Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY

The inflammatory bowel diseases (IBD) are described as complex, recurrent inflammatory conditions which are manifested as Crohn's disease (CD) and ulcerative colitis (UC). The common symptoms of IBD include debilitating/severe diarrhea, abdominal pain, weight loss, and chronic fatigue; events that may culminate in life-threatening complications. The pathogenesis of IBD has been characterized as complex/multi-factorial that includes disruption of intestinal epithelial barrier with consequent translocation of commensal microbial products as the prime event that instigates severe immune responses and intestinal inflammation.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 1
Maximum Age: 60
Healthy Volunteers: f
View:

• Age ≥ 18 years

• Both male and female will be

• Mild and moderate UC patients diagnosed and confirmed by endoscope

Locations
Other Locations
Egypt
Faculty of Medicine, Mansoura University
RECRUITING
Al Mansurah
Contact Information
Primary
Mostafa Bahaa, PhD
mbahaa@horus.edu.eg
0201025538337
Time Frame
Start Date: 2023-08-20
Estimated Completion Date: 2028-07-20
Participants
Target number of participants: 50
Treatments
Active_comparator: control group
Control group ( Mesalamine group, n =30 ) who will receive 1 g mesalamine three times daily for 6 months
Active_comparator: Dapagliflozin group
Patients will receive 1 g mesalamine three times daily plus dapagliflozin 10 mg once daily for 6 months
Sponsors
Leads: Mostafa Bahaa

This content was sourced from clinicaltrials.gov